The stock of Port Erin Biopharma Investments Ltd (LON:PEBI) gapped up by GBX 0.147 today and has GBX 9.27 target or 9.00% above today’s GBX 8.50 share price. The 5 months technical chart setup indicates low risk for the GBX 2.03M company. The gap was reported on Nov, 30 by Barchart.com. If the GBX 9.27 price target is reached, the company will be worth GBX 182,700 more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock decreased 1.45% or GBX 0.12 on November 30, hitting GBX 8.5. Port Erin Biopharma Investments Ltd (LON:PEBI) has risen 56.82% since May 3, 2016 and is uptrending. It has outperformed by 51.59% the S&P500.
Another recent and important Port Erin Biopharma Investments Ltd (LON:PEBI) news was published by Prnewswire.com which published an article titled: “Bontan changes its name to Portage Biotech Inc. and jurisdiction to BVI” on July 31, 2013.
Port Erin Biopharma Investments Limited invests in the biotechnology and biopharmaceutical sector. The company has a market cap of 2.03 million GBP. The Firm focuses on creating value for shareholders through investing in companies that have the potential to generate revenues through the development of biopharmaceutical drugs. It currently has negative earnings. The Firm invests in equity and equity-related products in both quoted companies, which offer the benefits of liquidity, and in unquoted companies, which offers the additional capital gains upon completion of an Initial Public Offering .
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.